Newsletter
Every new paper in this field, in your inbox.
Examining outcomes in metastatic colorectal cancer treatment, researchers conducted a review, analyzing six selected studies. Comparing surgical interventions on the liver and peritoneum, cytoreductive surgery with heated intraperitoneal chemotherapy showed comparable safety and survival outcomes to hepatectomy. This suggests a need for early integration of…
Analyzing 1614 cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) cases, researchers found that over 50% of patients traveled more than 100 miles for treatment. While regionalization showed no survival difference, those traveling further had fewer disparities but higher disease severity, raising concerns about access…
Global Experts Agree: In treating colorectal cancer with peritoneal metastases, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) extends median overall survival beyond 40 months. The consensus among 78% of international panelists highlights the conditionally recommended use of HIPEC post-surgery. The Dutch protocol, featuring mitomycin-C, gains…
In a phase II study, researchers explored the efficacy of intraperitoneal paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Among 53 patients, the treatment achieved a 73.6% 1-year overall survival rate, meeting the primary endpoint. The median survival time was 19.4…
In a study covering 5165 cases across 149 hospitals, ranging from low to high volume, no significant differences emerged in post-operative outcomes, including morbidity, mortality, length of stay, readmissions, or total cost. These findings challenge the notion that hospital volume influences patient outcomes in HIPEC…
In the clash of surgical approaches for advanced epithelial ovarian cancer, laparoscopic interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (L-CRS-HIPEC) outshone the open approach. With a significantly shorter hospital stay and faster return to systemic chemotherapy, L-CRS-HIPEC demonstrated comparable oncological outcomes. This study hints at…
Embracing cytoreductive surgery (CRS) for peritoneal malignancies faces diverse challenges worldwide. This review explores the adoption of CRS, crucial in gastrointestinal and gynecological cancers, revealing significant global disparities. High-income countries lead in establishing CRS programs, while barriers in low- and middle-income nations persist. Access to…
A study investigated the impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) on the quality of life (QoL) for patients taking opioids and psychotropic medications preoperatively. The research found that patients using these medications had worse baseline QoL but achieved similar scores to those…
A study examined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) using paclitaxel and cisplatin in 22 patients with gastric cancer and peritoneal metastasis. Results showed that this treatment was well-tolerated with favorable oncologic outcomes. Patients experienced high rates of complete cytoreduction and R0 resection,…
This study delves into the safety and effectiveness of combining hyperthermic intraoperative thoraco-abdominal chemotherapy (HITAC) with cytoreductive surgery (CRS) in patients with peritoneal carcinomatosis (PC) who need diaphragm resection. Researchers compared HITAC to traditional intraperitoneal chemotherapy (HIPEC). Results show that HITAC is a viable option…
